Characterization of the Molecular Mechanisms Involved in Delayed-Type Hypersensitivity Reactions to House Dust Mite, Diphencyprone, Nickel, and Tuberculin Purified Protein Derivative in Healthy Volunteers

NACompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 26, 2018

Primary Completion Date

March 12, 2020

Study Completion Date

June 9, 2020

Conditions
Delayed Type Hypersensitivity
Interventions
DRUG

Prednisone

40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.

DRUG

Placebo

8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days

Trial Locations (1)

H2K 4L5

Innovaderm Research Inc., Montreal

Sponsors
All Listed Sponsors
lead

Innovaderm Research Inc.

OTHER